Cytokinetics, Inc. : Cytokinetics to Host Investor Event Following Presentation of Results from ATOMIC-AHF at the European

      Cytokinetics, Inc. : Cytokinetics to Host Investor Event Following
Presentation of Results from ATOMIC-AHF at the European Society of Cardiology
                                Congress 2013

South San Francisco, CA, August 14, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today its plans to host an Investor Event following the
presentation of the results from the ATOMIC-AHF trial at the European Society
of Cardiology Congress 2013. The Cytokinetics event will be held on Tuesday,
September 3^rd from 2:00 PM - 3:00 PM Central European Time. The event will
be held in the Algiers Room, Village 4 at the RAI Convention Center in
Amsterdam, Netherlands. 

Cytokinetics will be represented by Robert Blum, President and Chief Executive
Officer; Dr.  Fady  I.  Malik,  Senior  Vice  President,  Research  and  Early 
Development; and  Dr.  Andrew A.  Wolff,  Senior Vice  President  of  Clinical 
Research and Development and Chief  Medical Officer. Also participating  will 
be Dr. John  R. Teerlink, Director  of the  Heart Failure Program  and of  the 
Clinical Echocardiography  Laboratory at  the San  Francisco Veterans  Affairs 
Medical Center, California, and Dr.  John J.V. McMurray, Professor of  Medical 
Cardiology at the University of Glasgow, Scotland, United Kingdom. 

Presentations and accompanying slides will be simultaneously webcast beginning
at 2:00 PM Central European Time (8:00 a.m. Eastern Time) and can be  accessed 
through the  Investor  Relations  section  of  the  Cytokinetics'  website  at 
www.cytokinetics.com. The live audio of the forum will also be accessible via
telephone to investors, members  of the news media  and the general public  by 
dialing either  (866) 999-CYTK  (2985)  (United States  and Canada)  or  (706) 
679-3078 (International) and typing in the passcode 31517709. 

An archived replay of the webcast will be available on the Presentations  page 
in the Investor Relations section of Cytokinetics' website until September 10,
2013. The replay will also be available via telephone from September 3,  2013 
at 2:00 p.m. Eastern Time until  September 10, 2013 by dialing (855)  859-2056 
(United States and Canada) or (404) 537-3406 (International) and typing in the
passcode 31517709.

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function for the  potential treatment of  serious diseases and  medical 
conditions.  Cytokinetics'  lead  drug  candidate  from  its  cardiac   muscle 
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment  of heart failure. Amgen  Inc. holds an  exclusive 
license worldwide to develop and commercialize omecamtiv mecarbil and  related 
compounds,   subject    to    Cytokinetics'    specified    development    and 
commercialization  participation   rights.   Cytokinetics   is   independently 
developing tirasemtiv,  a  fast  skeletal muscle  activator,  as  a  potential 
treatment for diseases  and medical conditions  associated with  neuromuscular 
dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials
program and has been granted orphan drug designation and fast track status  by 
the U.S. Food and Drug Administration and orphan medicinal product designation
by the European Medicines  Agency for the  potential treatment of  amyotrophic 
lateral  sclerosis,  a  debilitating  disease  of  neuromuscular   impairment. 
Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107,
a  skeletal  muscle  activator  structurally  distinct  from  tirasemtiv,  for 
non-neuromuscular indications. All of these  drug candidates have arisen  from 
Cytokinetics' muscle  biology focused  research  activities and  are  directed 
towards  the   cytoskeleton.  The   cytoskeleton  is   a  complex   biological 
infrastructure  that  plays  a  fundamental  role  within  every  human  cell. 
Additional   information    about   Cytokinetics    can   be    obtained    at 
www.cytokinetics.com.

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to planned presentations, and the properties and potential
benefits of  Cytokinetics'  drug  candidates. Such  statements  are  based  on 
management's current expectations,  but actual results  may differ  materially 
due to  various  risks  and  uncertainties, including,  but  not  limited  to, 
potential difficulties  or  delays  in the  development,  testing,  regulatory 
approval and production  of Cytokinetics' drug  candidates and potential  drug 
candidates  that  could  slow  or  prevent  clinical  development  or  product 
approval, including risks that current and past results of clinical trials  or 
preclinical studies may not  be indicative of  future clinical trials  results 
and that Cytokinetics' drug candidates and potential drug candidates may  have 
unexpected adverse  side  effects  or  inadequate  therapeutic  efficacy.  For 
further information regarding these and  other risks related to  Cytokinetics' 
business, investors should consult  Cytokinetics' filings with the  Securities 
and Exchange Commission.

Contact:
Cytokinetics, Inc.
Joanna L. Goldstein (Investors & Media)
(650) 624-3000

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
HUG#1723125